Name | Title | Contact Details |
---|
Carl Greenblatt founded G&W Laboratories, Inc. in 1919 upon his return from military service as a pharmacist with US forces in World War I. While establishing a reputation as an innovative specialist in suppository dosage forms, Carl guided G&W Laboratories with an uncompromising commitment to product integrity and customer service. In 1945, Carl’s son, Burton, also a registered pharmacist, returned from military service in World War II and joined the small but growing company. During the post-war years, G&W expanded its product line beyond suppositories, into creams, ointments, gels and liquids. G&W moved to a larger state-of-the-art laboratory and production facility, which now exceeds 180,000 square feet in South Plainfield, New Jersey. Continuing the high ethical standards and customer focus established by Carl and his son Burton Greenblatt, G&W is still family owned and operated. Burton’s son, Ronald, who joined the company in 1978 and now serves as Chief Executive Officer; and Ronald’s son, Aaron, who joined the company in 2009 after earning his Pharm.D. In addition to strong family ties the family hired Kurt Orlofski, who joined G&W as President and Chief Operating Officer in 2009.
Cyteir is a clinical-stage oncology company that is focused on the discovery and development of next-generation synthetically lethal therapies to treat cancer. The company is using its expertise in DNA damage response biology to advance a pipeline of novel drug candidates that selectively target key cancer vulnerabilities. Cyteir`s wholly owned lead compound, CYT-0851, is a potent and selective, oral investigational drug currently in a Phase 1/2 clinical trial for hematologic and solid tumors.
Black Diamond Therapeutics is a next-wave cancer precision medicine company. Black Diamond pioneered the development of selective medicines for patients with genetically defined cancers driven by oncogenes activated by allosteric mutations. Using its mutation, allostery, and pharmacology (MAP) computational and discovery platform, Black Diamond is uncovering new ways to functionally assess the mutational landscape of individual oncogenes – to discover and validate new targets and develop novel approaches to creating highly selective therapeutics. Black Diamond was founded by David M. Epstein, Ph.D., Elizabeth Buck, Ph.D., and Versant Ventures, and is the first new company to emerge from Versant`s Ridgeline Discovery Engine in Basel, Switzerland.
...your behavioral health specialty care provider
We are a healthcare solutions company that provides comprehensive and customized manufacturer patient support services and specialty pharmacy solutions. AppianRx leverages its unique and proprietary technology platform to deliver personalized services faster, smarter and more efficiently for patients, providers and manufacturer partners.